173 related articles for article (PubMed ID: 24671188)
1. Designing a high-throughput somatic mutation profiling panel specifically for gynaecological cancers.
Spaans VM; Trietsch MD; Crobach S; Stelloo E; Kremer D; Osse EM; Haar NT; van Eijk R; Muller S; van Wezel T; Trimbos JB; Bosse T; Smit VT; Fleuren GJ
PLoS One; 2014; 9(3):e93451. PubMed ID: 24671188
[TBL] [Abstract][Full Text] [Related]
2. CDKN2A(p16) and HRAS are frequently mutated in vulvar squamous cell carcinoma.
Trietsch MD; Spaans VM; ter Haar NT; Osse EM; Peters AA; Gaarenstroom KN; Fleuren GJ
Gynecol Oncol; 2014 Oct; 135(1):149-55. PubMed ID: 25072932
[TBL] [Abstract][Full Text] [Related]
3. A rapid, sensitive, reproducible and cost-effective method for mutation profiling of colon cancer and metastatic lymph nodes.
Fumagalli D; Gavin PG; Taniyama Y; Kim SI; Choi HJ; Paik S; Pogue-Geile KL
BMC Cancer; 2010 Mar; 10():101. PubMed ID: 20233444
[TBL] [Abstract][Full Text] [Related]
4. Next generation MUT-MAP, a high-sensitivity high-throughput microfluidics chip-based mutation analysis panel.
Schleifman EB; Tam R; Patel R; Tsan A; Sumiyoshi T; Fu L; Desai R; Schoenbrunner N; Myers TW; Bauer K; Smith E; Raja R
PLoS One; 2014; 9(3):e90761. PubMed ID: 24658394
[TBL] [Abstract][Full Text] [Related]
5. Highly multiplexed quantifications of 299 somatic mutations in colorectal cancer patients by automated MALDI-TOF mass spectrometry.
Xu C; Peng D; Li J; Chen M; Hu Y; Hou M; Shang Q; Liang Q; Li J; Li W; Wu X; Liu C; Hu W; Cai M; Zhang H; Chen G; Yu L; Zheng X; Jiang F; Luan J; Jin S; Ding C
BMC Med Genomics; 2020 Oct; 13(1):143. PubMed ID: 33008377
[TBL] [Abstract][Full Text] [Related]
6. Spatio-temporal mutation profiles of case-matched colorectal carcinomas and their metastases reveal unique de novo mutations in metachronous lung metastases by targeted next generation sequencing.
Kovaleva V; Geissler AL; Lutz L; Fritsch R; Makowiec F; Wiesemann S; Hopt UT; Passlick B; Werner M; Lassmann S
Mol Cancer; 2016 Oct; 15(1):63. PubMed ID: 27756406
[TBL] [Abstract][Full Text] [Related]
7. Multiplex mutation screening by mass spectrometry evaluation of 820 cases from a personalized cancer medicine registry.
Beadling C; Heinrich MC; Warrick A; Forbes EM; Nelson D; Justusson E; Levine J; Neff TL; Patterson J; Presnell A; McKinley A; Winter LJ; Dewey C; Harlow A; Barney O; Druker BJ; Schuff KG; Corless CL
J Mol Diagn; 2011 Sep; 13(5):504-13. PubMed ID: 21726664
[TBL] [Abstract][Full Text] [Related]
8. High-throughput detection of clinically relevant mutations in archived tumor samples by multiplexed PCR and next-generation sequencing.
Bourgon R; Lu S; Yan Y; Lackner MR; Wang W; Weigman V; Wang D; Guan Y; Ryner L; Koeppen H; Patel R; Hampton GM; Amler LC; Wang Y
Clin Cancer Res; 2014 Apr; 20(8):2080-91. PubMed ID: 24573554
[TBL] [Abstract][Full Text] [Related]
9. A novel liquidchip platform for simultaneous detection of 70 alleles of DNA somatic mutations on EGFR, KRAS, BRAF and PIK3CA from formalin-fixed and paraffin-embedded slides containing tumor tissue.
Li G; Luo X; He J; Zhu Z; Yu G; Qin H; Zeng T; Liu Z; Wu S; Xu J; Ren-Heidenreich L
Clin Chem Lab Med; 2011 Feb; 49(2):191-5. PubMed ID: 21118047
[TBL] [Abstract][Full Text] [Related]
10. Clinical significance of multiple gene detection with a 22-gene panel in formalin-fixed paraffin-embedded specimens of 207 colorectal cancer patients.
Gao XH; Yu GY; Hong YG; Lian W; Chouhan H; Xu Y; Liu LJ; Bai CG; Zhang W
Int J Clin Oncol; 2019 Feb; 24(2):141-152. PubMed ID: 30612269
[TBL] [Abstract][Full Text] [Related]
11. Rapid targeted somatic mutation analysis of solid tumors in routine clinical diagnostics.
Magliacane G; Grassini G; Bartocci P; Francaviglia I; Dal Cin E; Barbieri G; Arrigoni G; Pecciarini L; Doglioni C; Cangi MG
Oncotarget; 2015 Oct; 6(31):30592-603. PubMed ID: 26435479
[TBL] [Abstract][Full Text] [Related]
12. Determination of somatic oncogenic mutations linked to target-based therapies using MassARRAY technology.
Ibarrola-Villava M; Fleitas T; Llorca-Cardeñosa MJ; Mongort C; Alonso E; Navarro S; Burgues O; Vivancos A; Cejalvo JM; Perez-Fidalgo JA; Roselló S; Ribas G; Cervantes A
Oncotarget; 2016 Apr; 7(16):22543-55. PubMed ID: 26968814
[TBL] [Abstract][Full Text] [Related]
13. Mutation scanning using MUT-MAP, a high-throughput, microfluidic chip-based, multi-analyte panel.
Patel R; Tsan A; Tam R; Desai R; Spoerke J; Schoenbrunner N; Myers TW; Bauer K; Smith E; Raja R
PLoS One; 2012; 7(12):e51153. PubMed ID: 23284662
[TBL] [Abstract][Full Text] [Related]
14. Clinical significance of frequent somatic mutations detected by high-throughput targeted sequencing in archived colorectal cancer samples.
Dallol A; Buhmeida A; Al-Ahwal MS; Al-Maghrabi J; Bajouh O; Al-Khayyat S; Alam R; Abusanad A; Turki R; Elaimi A; Alhadrami HA; Abuzenadah M; Banni H; Al-Qahtani MH; Abuzenadah AM
J Transl Med; 2016 May; 14(1):118. PubMed ID: 27146902
[TBL] [Abstract][Full Text] [Related]
15. Mutational screening of RET, HRAS, KRAS, NRAS, BRAF, AKT1, and CTNNB1 in medullary thyroid carcinoma.
Schulten HJ; Al-Maghrabi J; Al-Ghamdi K; Salama S; Al-Muhayawi S; Chaudhary A; Hamour O; Abuzenadah A; Gari M; Al-Qahtani M
Anticancer Res; 2011 Dec; 31(12):4179-83. PubMed ID: 22199277
[TBL] [Abstract][Full Text] [Related]
16. High throughput interrogation of somatic mutations in high grade serous cancer of the ovary.
Matulonis UA; Hirsch M; Palescandolo E; Kim E; Liu J; van Hummelen P; MacConaill L; Drapkin R; Hahn WC
PLoS One; 2011; 6(9):e24433. PubMed ID: 21931712
[TBL] [Abstract][Full Text] [Related]
17. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.
De Roock W; Claes B; Bernasconi D; De Schutter J; Biesmans B; Fountzilas G; Kalogeras KT; Kotoula V; Papamichael D; Laurent-Puig P; Penault-Llorca F; Rougier P; Vincenzi B; Santini D; Tonini G; Cappuzzo F; Frattini M; Molinari F; Saletti P; De Dosso S; Martini M; Bardelli A; Siena S; Sartore-Bianchi A; Tabernero J; Macarulla T; Di Fiore F; Gangloff AO; Ciardiello F; Pfeiffer P; Qvortrup C; Hansen TP; Van Cutsem E; Piessevaux H; Lambrechts D; Delorenzi M; Tejpar S
Lancet Oncol; 2010 Aug; 11(8):753-62. PubMed ID: 20619739
[TBL] [Abstract][Full Text] [Related]
18. Somatic DNA Mutation Analysis.
O'Grady A; Cummins R
Methods Mol Biol; 2017; 1606():219-233. PubMed ID: 28502004
[TBL] [Abstract][Full Text] [Related]
19. Targeted Next Generation Sequencing as a Reliable Diagnostic Assay for the Detection of Somatic Mutations in Tumours Using Minimal DNA Amounts from Formalin Fixed Paraffin Embedded Material.
de Leng WW; Gadellaa-van Hooijdonk CG; Barendregt-Smouter FA; Koudijs MJ; Nijman I; Hinrichs JW; Cuppen E; van Lieshout S; Loberg RD; de Jonge M; Voest EE; de Weger RA; Steeghs N; Langenberg MH; Sleijfer S; Willems SM; Lolkema MP
PLoS One; 2016; 11(2):e0149405. PubMed ID: 26919633
[TBL] [Abstract][Full Text] [Related]
20. KRas and BRaf mutational status analysis from formalin-fixed, paraffin-embedded tissues using multiplex polymerase chain reaction-based assay.
Jakubauskas A; Griskevicius L
Arch Pathol Lab Med; 2010 Apr; 134(4):620-4. PubMed ID: 20367313
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
